When compared to lab-based PCR testing.
Easy to use
Ready for immediate use with minimal preparation time or training.
Use existing CPT codes available here.
Scalable with future care offerings, including a wide range of tests.
Please confirm with your organization regarding accurate CPT coding.
The Cue® Integrated Care Platform
How it works
The streamlined Cue system is designed to provide you with the accuracy and speed you need to treat patients in real-time — all from a portable device that fits in the palm of your hand.
Efficient and intelligent, the rechargeable Cue Reader swiftly processes tests and communicates the results to the Cue Health App via Bluetooth®. Up to six Readers can be connected to the Cue Health App at one time for increased testing capacity.
Lab-quality testing made easy
Our sample-specific, single use tests are designed to deliver complex chemistry simply and safely. Each cartridge comes ready for testing and there’s no mixing required.
More than just a test
Cue’s Dashboard and App work together to help you manage patient or employee profiles, communicate results, analyze trends, and comply with reporting.
Future Tests and Services
A holistic approach to health
Designed as a complete diagnostic system, Cue’s future care offerings feature a wide range of tests and services including respiratory health, sexual health, women’s health, and overall wellness — all compatible with the Cue Reader.
A scalable model for modern healthcare
Whether you’re running a large healthcare network or an intimate family practice, Cue streamlines your ability to deliver value-based care with fast, highly accurate test results on demand.
Automated Data Reporting
Streamlined and compliant data reporting you can rely on.
Easy-to-use system requires no formal training and minimal set up.
Fast test processing and the ability to run multiple tests simultaneously.
No Calibration or Servicing
Easy to maintain system with no downtime needed for calibration or servicing.
Portable & Compact
Minimal footprint, easily transported for remote or offsite use.
Low price of entry and easily scalable within an organization or across a network.
Access valuable insights and management tools, including API integration with existing EHR/EMR systems.
Fully compatible with future Cue tests.
Interested in bringing Cue to your organization?
Connect with our team to discuss the right solution for your healthcare organization or request a demo of our technology.
Shop our full line of products
Already know exactly what you want or just need to restock on a few essentials? Our self-serve online store is always open.
Cue COVID-19 Tests - 10 Pack
Cue COVID-19 External Control Swabs - 3 Pack
Cue Reader + 20 COVID-19 Tests
Bundle priceShop Now
3 Cue Readers + 50 COVID-19 Tests
Bundle priceShop Now
6 Cue Readers + 100 COVID-19 Tests
Bundle priceShop Now
Get Cue through your trusted distributor
A dashboard that works for you
The Cue Dashboard empowers you with valuable insights and management capabilities, including analytics, reporting solutions, and API integrations with existing EHR/EMR systems.
With several tiers of service, our team can help you find the right solution for your organization. To learn more or purchase the Cue Dashboard, please contact us directly — the Dashboard is not currently included with online orders.Contact us
Cue’s COVID-19 Test
Accurate diagnosis is critical to reducing risk of COVID-19 related hospitalization
Discover how Cue® empowers you to treat patients within the critical timeframe.
How Cue compares to other COVID‑19 tests
Cue has the accuracy and early detection benefits of lab-testing and the convenience of a rapid antigen test.
Percent accuracy and sensitivity are estimates based on published information. Individual test performance depends on several factors, including viral load (strength of infection based on time since initial infection or exposure), testing conditions, and vaccination status of individual).
- Based on Cue COVID-19 Test for Home and OTC Use EUA Instructions for Use.
- Range based on competitor Rt-PCR Assay Instructions for Use Claims.
- Based on competitor Antigen Assay Instructions for Use Claims.
- Based on FH Health Inc. Poster “Performance of the Cue COVID-19 Test: prospective clinical verification and operational insights from a multi-centre clinic service delivery model”.
- Based on JAMA Internal Medicine “Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection”.
Behind the science
The accuracy and efficacy of Cue’s diagnostic capabilities have been put to the test by some of the most reputable researchers in the industry.
Mayo Clinic conducted an independent study of Cue’s COVID-19 test in a point-of-care setting,
comparing the accuracy of results with lab-based PCR tests.
97.8% of Cue’s results matched those of the PCR tests in the Mayo Clinic study.
Click below to explore the study in more depth.
Proven results at point‑of‑care
Albertsons implements a nationwide COVID-19 testing program with Cue.Learn more
Frequently Asked Questions
The Cue COVID-19 Test for CLIA Certified Healthcare Providers and Laboratories (Cue COVID-19 Test) is streamlined, easy-to-use, and doesn’t require any specific training to operate.
The Cue COVID-19 Test is authorized for use in point-of-care settings by laboratories or other organizations certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a and meets the requirements to perform high, moderate, or waived complexity tests. The test is also authorized for use in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
For directions, conditions of authorization, precautions, and additional information, please see the Cue COVID-19 Test Instructions For Use (IFU).
As of January 15, 2022, private insurance companies in the United States are required to reimburse their members for COVID-19 tests, per a federal requirement.
Methods and amounts of reimbursement vary by payor, and we encourage you to check with specific payors about their policies regarding reimbursement.
Some providers use 87635 as the CPT code for reimbursement: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]).
The coding information contained here is for informational purposes only and is not a guarantee of coverage or reimbursement for any product or service. We recommend you consult with our CPT code advisors for guidance.
Cue COVID-19 Test for CLIA Certified Healthcare Providers and Laboratories
The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for the Cue COVID-19 Test for Professional Use. The Cue COVID-19 Test may be used to test symptomatic and asymptomatic individuals for the detection of nucleic acid from SARS-CoV-2. Testing may be performed by CLIA certified laboratories or at the point-of-care (POC), i.e., in patient care settings, operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
The Cue COVID-19 Test for Home and Over The Counter (OTC) Use
The FDA granted the Cue COVID-19 Test Emergency Use Authorization (EUA) for Home and Over The Counter (OTC) Use for the detection of nucleic acid from SARS-CoV-2 in symptomatic and asymptomatic individuals, ages 2 years and older. Tests may be purchased without a prescription and self-administered by adults or administered on minors with adult assistance.
- Authorized Laboratories using the Cue COVID-19 Test must include all authorized fact sheets along with test result reports. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized Laboratories must follow Cue’s COVID-19 Test Instructions For Use. Deviations from the authorized procedures, including authorized clinical specimen types and authorized control materials required to use the Cue COVID-19 Test, are not permitted.
- Authorized Laboratories that receive the Cue COVID-19 Test must notify the relevant public health authorities of their intent to run the product prior to initiating testing.
- Authorized Laboratories using the Cue COVID-19 Test must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- Authorized Laboratories must collect information on the performance of the Cue COVID-19 Test and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUAReporting@fda.hhs.gov) and Cue Health Inc. Technical Support (email@example.com) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the Cue COVID-19 Test of which they become aware.
- All operators using the Cue COVID-19 Test must be able to perform and interpret the test results, use appropriate personal protective equipment, and use the product in accordance with the authorized labeling.
- Authorized Laboratories using the Cue COVID-19 Test must ensure that any records associated with this EUA are maintained until otherwise notified by the FDA. Such records will be made available to the FDA for inspection upon request.
The reimbursement CPT code for Cue’s COVID-19 Test is: 87635 — Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
The coding information contained here is for informational purposes only, and is not a guarantee of coverage or reimbursement for any product or service.
COVID-19 Test Fact Sheet for Healthcare ProfessionalsDownload
COVID-19 Test Instructions For Use (IFU)Download
Mpox Test Instructions For Use (IFU)Download
COVID-19 Test Quick Reference InstructionsDownload
COVID-19 Test FDA EUA LetterDownload
Mpox Test FDA EUA LetterDownload
The Cue COVID-19 Test and the Cue Mpox (Monkeypox) Molecular Test have not been FDA cleared or approved, but have been authorized for emergency use by FDA under EUAs. These products have been authorized only for the detection of nucleic acid from SARS-CoV-2 or monkeypox virus, respectively, not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declarations that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of infection with COVID-19 or the monkeypox virus, including in vitro diagnostics that detect and/or diagnose infection with non-variola Orthopoxvirus, under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the relevant declaration is terminated or authorization is revoked sooner.
This document may depict certain future planned care offerings which are subject to completion of development and/or may require regulatory authorization, clearance, or approval before they can be commercialized. For products and other disclaimers, visit cuehealth.com/docs.